Fate Therapeutics
FATE
#8582
Rank
โ‚ฌ0.24 B
Marketcap
2,04ย โ‚ฌ
Share price
-5.76%
Change (1 day)
68.37%
Change (1 year)

Fate Therapeutics (FATE) - Cash on Hand

Cash on Hand as of June 2026 : โ‚ฌ0.13 Billion

According to Fate Therapeutics 's latest financial reports the company has โ‚ฌ0.13 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Fate Therapeutics - Cash on Hand chart (from 2012 to 2026)

Cash on Hand by year

Year Cash on Hand Change
2025-12-31โ‚ฌ0.17 B-35.35%
2024-12-31โ‚ฌ0.26 B-5.94%
2023-12-31โ‚ฌ0.28 B-29.89%
2022-12-31โ‚ฌ0.40 B-25.22%
2021-12-31โ‚ฌ0.54 B38.52%
2020-12-31โ‚ฌ0.39 B98.63%
2019-12-31โ‚ฌ0.19 B12.5%
2018-12-31โ‚ฌ0.17 B108.84%
2017-12-31โ‚ฌ84.13 M-3.92%
2016-12-31โ‚ฌ87.57 M47.74%
2015-12-31โ‚ฌ59.27 M46.82%
2014-12-31โ‚ฌ40.37 M3.18%
2013-12-31โ‚ฌ39.12 M469.58%
2012-12-31โ‚ฌ6.86 M39.68%
2011-12-31โ‚ฌ4.91 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
Becton Dickinson
BDX
โ‚ฌ0.63 B 361.08%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
โ‚ฌ0.70 B 412.77%๐Ÿ‡บ๐Ÿ‡ธ USA
PTC Therapeutics
PTCT
โ‚ฌ1.98 B 1,349.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
โ‚ฌ0.34 B 153.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Avidity Biosciences
RNAM
โ‚ฌ1.50 B 1,003.51%๐Ÿ‡บ๐Ÿ‡ธ USA